About Mpex Pharmaceuticals
Mpex Pharmaceuticals is a Healthcare company based in San Diego (United States) founded in 2001, and was acquired by Axcan Pharma in April 2011. Therapies for antibiotic-resistant gram-negative infections are developed. Mpex Pharmaceuticals has raised $59.5 million across 2 funding rounds from investors including HBM Healthcare Investments, Axcan Pharma and Investor Growth Capital. The company has 33 employees. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Mpex Pharmaceuticals, Inc. Its competitors include Avidity Biosciences, Sutro Biopharma and Paratek Pharma; 3 of its 3 listed competitors have raised funding.
Company details
Mpex Pharmaceuticals was founded in 2001 in San Diego, United States, within the biopharmaceutical sector. Focus is placed on developing therapies to combat antibiotic resistance, especially in gram-negative organisms. The lead product, Aeroquinan aerosol formulation of levofloxacinis undergoing Phase 3 clinical trials for pulmonary infections associated with cystic fibrosis. Operations center on infectious disease treatments, and the company was acquired by Axan in 2011.
- Headquarters San Diego, United States
- Employees 33
- Stage Acquired
- SectorsHealthcare
- Website mpexpharma.com
- Social LinkedIn
- Acquired by Axcan Pharma (Apr 2011)
- Legal Name Mpex Pharmaceuticals, Inc.
- Total Equity Funding$59.5M (USD)
in 2 rounds
- Latest Funding Round$27.5M (USD), Series D
Feb 2009
- InvestorsHBM Healthcare Investments
& 9 more
- Employee Count33
- Acquired byAxcan Pharma
(Apr 2011)
Funding Insights of Mpex Pharmaceuticals
Mpex Pharmaceuticals has successfully raised a total of $59.5M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $27.5 million completed in February 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $59.5M
- Total Rounds 2
- Last Round Series D — $27.5M
- First Round $32M
(Aug 2005)
- Investors Count 9
All 2 funding rounds of Mpex Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2009 | $27.5M | Series D | – | Investor Growth Capital | |
| Aug 2005 | $32M | Series B | – | SV Health Investors, HBM Healthcare Investments |
10 investors in total: 10 institutional.
Investors in Mpex Pharmaceuticals
Mpex Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HBM Healthcare Investments, Axcan Pharma and Investor Growth Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors | investorgrowthcapital.com | New York, United States | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
US Life-Sciences sectors are targeted for investment by Aberdare Ventures. | aberdare.com | San Francisco, United States | ||
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
| rivervest.com | ||||
Capital and strategic advice are provided to emerging businesses. | 1976 | wsig.com | San Diego, United States | |
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
| charitableleadership.org | ||||
Gastrointestinal disorders are treated via developed pharmaceutical products. | 1982 | axcan.com | Quebec City, Canada |
Investor details for Mpex Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Mpex Pharmaceuticals
4 dated milestones of Mpex Pharmaceuticals across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Mpex Pharmaceuticals is founded.
- Funding First funding round of $32.0M.
- Funding Latest funding round, Series D, of $27.5M.
- Exit Acquired by Axcan Pharma.
Competitors of Mpex Pharmaceuticals
Mpex Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Paratek Pharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. |
Detailed competitors of Mpex Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mpex Pharmaceuticals
Websites that share an audience with Mpex Pharmaceuticals (mpexpharma.com).
Websites whose visitors overlap most with Mpex Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
acmeglobal.com | acmeglobal.com | 100% | #947,987 | – | |
antibiotics-info.org | antibiotics-info.org | 99% | – |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Mpex Pharmaceuticals (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mpex Pharmaceuticals
Complete news archive for Mpex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mpex Pharmaceuticals
Mpex Pharmaceuticals was founded in 2001 and raised its 1st funding round 4 years after it was founded.
Mpex Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Mpex Pharmaceuticals is a funded company, having raised a total of $59.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $32M, raised on Aug 2005.
Mpex Pharmaceuticals has 33 employees.
Mpex Pharmaceuticals was founded in 2001 in San Diego, United States, within the biopharmaceutical sector. Focus is placed on developing therapies to combat antibiotic resistance, especially in gram-negative organisms. The lead product, Aeroquinan aerosol formulation of levofloxacinis undergoing Phase 3 clinical trials for pulmonary infections associated with cystic fibrosis. Operations center on infectious disease treatments, and the company was acquired by Axan in 2011.
Mpex Pharmaceuticals's top competitors include Sutro Biopharma, Avidity Biosciences and Paratek Pharma.
Mpex Pharmaceuticals has 10 investors. Key investors include HBM Healthcare Investments, Axcan Pharma, Investor Growth Capital, SV Health Investors, and Aberdare Ventures.
Mpex Pharmaceuticals operates through Mpex Pharmaceuticals, Inc..
Yes. Mpex Pharmaceuticals was acquired by Axcan Pharma in April 2011.